Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02922166|
Recruitment Status : Recruiting
First Posted : October 4, 2016
Last Update Posted : February 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Fear Anxiety||Drug: SRX246 Drug: Placebo||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||47 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans|
|Actual Study Start Date :||February 3, 2017|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
Placebo Comparator: Placebo
Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
- Change in startle reflex between SRX246 and Placebo [ Time Frame: up to 7 days ]Subjects will be exposed to none (N), predictable (P) and unpredictable (U) acoustic and electric shocks.
- Change in emotional expression recognition between SRX246 and Placebo [ Time Frame: up to 7 days ]Subjects will be shown pictures of faces exhibiting anger, disgust, fear, happiness, sadness and surprise.
- Change in State Anxiety Scale between SRX246 and Placebo [ Time Frame: up to 7 days ]Subjects will rate their anxiety level during assessments using a self-administered rating scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02922166
|Contact: Tiffany Lago, MDfirstname.lastname@example.org|
|United States, Maryland|
|National Institute of Mental Health||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: Tiffany Lago, MD 301-402-4897 email@example.com|
|Principal Investigator: Christian Grillon, PhD|